KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Current Assets (2016 - 2026)

Abbott Laboratories' Current Assets history spans 18 years, with the latest figure at $25.5 billion for Q1 2026.

  • On a quarterly basis, Current Assets rose 10.17% to $25.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $25.5 billion, a 10.17% increase, with the full-year FY2025 number at $26.0 billion, up 9.89% from a year prior.
  • Current Assets hit $25.5 billion in Q1 2026 for Abbott Laboratories, down from $26.0 billion in the prior quarter.
  • Over the last five years, Current Assets for ABT hit a ceiling of $26.0 billion in Q4 2025 and a floor of $22.4 billion in Q1 2024.
  • Historically, Current Assets has averaged $24.0 billion across 5 years, with a median of $23.8 billion in 2024.
  • Biggest five-year swings in Current Assets: increased 10.29% in 2022 and later decreased 10.13% in 2023.
  • Tracing ABT's Current Assets over 5 years: stood at $25.2 billion in 2022, then decreased by 10.13% to $22.7 billion in 2023, then grew by 4.35% to $23.7 billion in 2024, then rose by 9.89% to $26.0 billion in 2025, then dropped by 1.88% to $25.5 billion in 2026.
  • Business Quant data shows Current Assets for ABT at $25.5 billion in Q1 2026, $26.0 billion in Q4 2025, and $24.8 billion in Q3 2025.